Renal Integrase Study

HIV Clinical Trial

Official title:

A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/Emtricitabine With Raltegravir or Dolutegravir or Elvitegravir/Cobicistat on Renal Tubular Function and Renal Transporters in HIV-1 Antiretroviral naïve Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02351908
• Other study ID #: SSAT 066
• Status: Completed
• Phase: Phase 4
• First received: January 21, 2015
• Last updated: June 26, 2017
• Start date: March 2015
• Est. completion date: April 2017

Study information

• Verified date: April 2017
• Source: St Stephens Aids Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to observe the safety of Truvada® (TDF/FTC) in relation to its impact on kidney function combined with different Integrase Inhibitors (Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir), when given to patients who are commencing treatment for HIV infection for the first time.

All three combinations (Raltegravir + Truvada®, Dolutegravir + Truvada® and Stribild®, a single pill which contains Elvitegravir/Cobicistat/Truvada®) are currently recommended by the national guide-lines and used in standard clinical practice.

Description:

The study will monitor kidney function, and compare the safety and effectiveness of Truvada® when taken with Dolutegravir, or Elvitegravir/Cobicistat or Raltegravir, over the first 48 weeks of treatment in HIV-1 antiretrovirals naïve patients.

The safety and how well these drug combinations are tolerated will be determined based on physical examinations, laboratory tests, and questions about any problems the participant might experience during the study. As part of this trial, levels of HIV-1 in the blood and urinary markers of kidney function and inflammatory markers will be measured at various times during the study.

The total duration of participant involvement in the trial will be up to 48 weeks, with up to 45 days between the screening and baseline visits. Participants will need to visit the clinic 6 times within the 48 weeks.

Once participants have been confirmed to be eligible to participate in the study, participants will attend for a baseline visit (day 1) where they will be randomly assigned to receive one of the three treatments listed below:

• Treatment Arm 1: Stribild® (EVG/COBI/FTC/TDF) 1 tablet once a day

• Treatment Arm 2: Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® 1 tablet once a day

• Treatment Arm 3: Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® 1 tablet once a day

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: April 2017
• Est. primary completion date: April 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

1. Is male or female aged 18 years or above

2. Has documented HIV-1 infection

3. Has signed the Informed Consent Form voluntarily

4. Is willing to comply with the protocol requirements, including dosing schedules of each regimen

5. Has a HIV-plasma viral load at screening >1000 copies/mL

6. Has any CD4 cell count

7. Has never been exposed to ART (other than via PEP or PREP, not associated with acquisition of HIV)

8. Has an estimated glomerular filtration rate (MDRD method) >60 ml/min

9. Has no known resistance to TDF and FTC or to Integrase Inhibitors. HIV resistance test has to be dated no more than 1 year prior screening date. Only a RT/Pr gene resistance test is re-quired.

10. If female and of childbearing potential, she is using effective birth control methods (as agreed by the investigator) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the end of the trial (or after last intake of investigational ARVs); Dosing of the OCP may need to be adjusted if randomized to the Stribild® arm.

Note: Women who are postmenopausal for least 2 years, women with total hysterectomy, and women who have a tubal ligation are considered of non-childbearing potential

11. If a heterosexually active male, he is using effective birth control methods and is willing to con-tinue practising these birth control methods during the trial and until follow-up visit

Exclusion Criteria:

1. Is infected with HIV-2

2. Is using any concomitant therapy disallowed as per SPC for the study drugs

3. Has a currently active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection-1993) with the following exceptions (must be discussed with the sponsor prior to enrolment):

• Stable cutaneous Kaposi's Sarcoma (no pulmonary or gastrointestinal involvement other than oral lesions) unlikely to require systemic therapy during the trial period

• CD4 count less than 200 cells/mm3 Note: Primary and secondary prophylaxis for an AIDS defining illness is allowed

4. Has diabetes or any known or established renal disease or abnormality regardless of if stable

5. Has presence at screening of proteinurea and or a urinary protein/creatinine ratio >30

6. Has untreated / not well controlled hypertension

7. Has acute viral hepatitis including, but not limited to, A, B, or C

8. Has chronic hepatitis B or chronic hepatitis C with AST and/or ALT >5 x ULN Note:

Subjects co-infected with chronic HCV (but not B) can enter the trial if clinically stable and not expected to require treatment during the trial period.

9. Has received any investigational drug within 30 days prior to the trial drug administration

10. No baseline resistance test to reverse transcriptase inhibitors available

11. Clinically significant allergy or hypersensitivity or other contraindication to any trial medication or excipients

12. If female, she is pregnant or breastfeeding

13. Screening blood results with any grade 3 / 4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).

14. Clinical or laboratory evidence of significantly decreased hepatic function or decompensation: INR > 1.5 or albumin < 30g/L

15. Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.

16. Is not using high protein training supplements such as creatinine or intermittently following exclusionary or high protein diets

17. Is not receiving medication with known relevant drug interactions or contraindications to any of the trial medications

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)

• Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet

• Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)

Locations

Country	Name	City	State
United Kingdom	SSAT Clinical Research Facility	London

Sponsors (2)

Lead Sponsor	Collaborator
St Stephens Aids Trust	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in retinol-binding protein/creatinine ratio (PCR) with each regimen over 24 weeks.	The change in retinol-binding protein/creatinine ratio (PCR) with each regimen over 24 weeks (measured via nephelometric assay run on Siemens BNII nephelometer).	24 weeks
Secondary	Change in retinol-binding protein/creatinine ratio with each regimen over 12 and 48 weeks.	The change in retinol-binding protein/creatinine ratio (PCR) with each regimen over 12 and 48 weeks (measured via nephelometric assay run on Siemens BNII nephelometer)	48 weeks
Secondary	eGFR	The variation from baseline of eGFR (C-G, MDRD with creatinine, CKD-EPI with creatinine / cystatin-C), creatinine, ß2- and alpha1- microglobulin excretion, urinary albumin and pro-tein/creatinine ratio, urinary cystatin-C / creatinine ratio, fractional phosphate excretion (fasted plasma PO4 and urinary spot phosphate), plasma urate and rates of normoglycemic glycosuria on each regimen at week 4, 12, 24, 36, and 48 of therapy.	48 weeks
Secondary	Virologic response	The proportion of patients achieving virologic response (HIV RNA < 40 cp/mL) on each regimen at week 4, 12, 24, 36 and 48.	48 weeks
Secondary	Immunologic markers	The changes in immunologic markers (CD4+, CD8+, ratio) at weeks 4, 12, 24, 36 and 48 of therapy with each regimen.	48 weeks
Secondary	Inflammatory markers	The changes in inflammatory markers (hsCRP, IL-6, d-dimer) at weeks 4, 12, 24 and 48 of therapy with each regimen.	48 weeks
Secondary	Metabolic markers	The changes, from baseline in metabolic markers: lipids (TC, LDL, HDL, TGs), at 4, 12, 24, 36 and 48 weeks of therapy, and in insulin, fasting glucose and HOMA-i at 24 weeks of therapy with each regimen.	48 weeks
Secondary	Tenofovir concentration	To measure tenofovir concentration (Ctrough 12 or 24) in plasma and urine, at week 4 of treat-ment with each regimen.	4 weeks
Secondary	Genetic polymorphisms	Relationship between genetic polymorphisms and exposure to the studied drugs.	48 weeks